1. Home
  2. IMMX vs HYI Comparison

IMMX vs HYI Comparison

Compare IMMX & HYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$6.34

Market Cap

306.2M

Sector

Health Care

ML Signal

HOLD

Logo Western Asset High Yield Defined Opportunity Fund Inc.

HYI

Western Asset High Yield Defined Opportunity Fund Inc.

HOLD

Current Price

$11.13

Market Cap

252.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMX
HYI
Founded
2014
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
306.2M
252.7M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
IMMX
HYI
Price
$6.34
$11.13
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$12.00
N/A
AVG Volume (30 Days)
1.0M
50.6K
Earning Date
11-07-2025
01-01-0001
Dividend Yield
N/A
9.59%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.34
$10.99
52 Week High
$7.73
$12.24

Technical Indicators

Market Signals
Indicator
IMMX
HYI
Relative Strength Index (RSI) 65.80 49.62
Support Level $5.73 $11.11
Resistance Level $6.33 $11.20
Average True Range (ATR) 0.48 0.05
MACD 0.14 -0.00
Stochastic Oscillator 93.78 43.10

Price Performance

Historical Comparison
IMMX
HYI

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

About HYI Western Asset High Yield Defined Opportunity Fund Inc.

Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.

Share on Social Networks: